HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral

Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consens

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envud

California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: A

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s

Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension

Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates

– Favorable long-term safety and tolerability profile remained consistent with previously reported d

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral

Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded

Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeuci

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory disea

Chardan Capital analyst Janani Sundararajan maintains Alumis (NASDAQ:ALMS) with a Buy and raises

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases us

Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & U

Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and raises the

Guggenheim analyst Yatin Suneja maintains Alumis (NASDAQ:ALMS) with a Buy and raises the price ta

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out

HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Alumis (NASDAQ:ALMS) from Buy to Ne

Alumis (NASDAQ:ALMS) reported quarterly losses of $(0.74) per share which beat the analyst consensus

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoria

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a

ALMS stock drops 11% as investors lock in a 239% yearly gain. Analyze the support levels and technic

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and raises the pr

Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at be

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality o

Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psori

– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful

– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of env

Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-s

AXQ Capital LP bought a new stake in Alumis Inc. (NASDAQ: ALMS) in the third quarter, according to t

Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 36.

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-st

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases w

The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aim

On January 2, 2026, Alumis Inc. (the "Company") and its wholly-owned subsidiary Acelyrin, In